<div id="readability-page-1"><div>By Connor Hart Genentech, a member of the Roche Group, said the U.S. Food and Drug Administration approved its treatment for follicular lymphoma. The therapy, Lunsumio VELO, can be used to treat adult patients with relapsed or refractory follicular lymphoma, a type of cancer of the lymphatic system, following two or more lines of systemic therapy, the company said Monday. Lunsumio VELO reduces administration time with an approximately one-minute injection, compared with an intravenous infusion of up to four hours, according to Genentech. &#34;With this FDA approval, treatment can now be administered in just one minute, which significantly reduces the time patients spend in the clinic and helps to align care with their individual needs and preferences,&#34; Levi Garraway, chief medical officer and head of global product development, said. Lunsumio VELO's approval is based on the primary analysis of a recent study, in which patients receiving the treatment showed a 75% objective response rate and a 59% complete response rate, Genentech said. Write to Connor Hart at connor.hart@wsj.com (END) Dow Jones Newswires12-22-25 0739ET</div></div>

羅氏(ADR)

基因泰克（Genentech），羅氏集團的一部分，已獲得 FDA 對 Lunsumio VELO 的批准，該藥物用於治療複發性或難治性濾泡性淋巴瘤。這種療法顯著縮短了給藥時間，僅需一分鐘注射，而不是四小時的輸注。該批准基於一項研究，顯示出 75% 的客觀反應率和 59% 的完全反應率。這一進展符合患者對更高效治療選擇的需求

基因泰克獲得 FDA 批准用於淋巴瘤治療